The intestinotrophic peptide, GLP-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib

Clinical Cancer Research

Volumn 13, Issue 17, 2007, Pages 5170-5175

  Hare, Kristine Juul ^a   Hartmann, Bolette ^b   Kissow, Hannelouise ^a   Holst, Jens Juul ^b   Poulsen, Steen Seier ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GLUCAGON LIKE PEPTIDE 2; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATROPHY; COLON TUMOR; COLONOSCOPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; ENTEROPATHY; FEMALE; MONOTHERAPY; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; ANIMAL; BODY WEIGHT; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; INTESTINE; ORGAN SIZE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ATROPHY; BODY WEIGHT; FEMALE; GLUCAGON-LIKE PEPTIDE 2; INTESTINES; MICE; MICE, INBRED C57BL; ORGAN SIZE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34548820977     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0574     Document Type: Article

References (47)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
2. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001;8:3-9.
3. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:1850-5.
4. Rubin GJ, Melhem MF, Gooding WE, et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32.
5. Wells A. EGF receptor. Int J Biochem Cell Biol 1999;31:637-43.
6. Meyers MB, Shen WP, Spengler BA, et al. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J Cell Biochem 1988;38:87-97.
7. Di Gennaro E, Barbarino M, Bruzzese F, et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ("Iressa"), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 2003;195:139-50.
8. Ranson M. ZD1839 (Iressa): formore than just non-small cell lung cancer. Oncologist 2002;7 Suppl 4:16-24.
9. Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 2005;10:579-89.
10. Messersmith WA, Laheru DA, Senzer NN, et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 2004;10:6522-7.
11. Berlanga-Acosta J, Playford RJ, Mandir N, Goodlad RA. Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. Gut 2001;48:803-7.
12. Chailler P, Menard D. Ontogeny of EGF receptors in the human gut. Front Biosci 1999;4:D87-101.
13. Wong WM, Wright NA. Epidermal growth factor, epidermal growth factor receptors, intestinal growth, and adaptation. JPEN J Parenter Enteral Nutr 1999;23:S83-8.
14. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
15. Giaccone G. The role of gefitinib in lung cancer treatment. Clin Cancer Res 2004;10:4233-7s.
16. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-50.
17. Dawson NA, Guo C, Zak R, et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 2004;10:7812-9.
18. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002;7 Suppl 4:2-8.
19. Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol 1997;273:E77-84.
20. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 1996;93:7911-6.
21. Tsai CH, Hill M, Drucker DJ. Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am J Physiol 1997;272:G662-8.
22. Hartmann B, Thulesen J, Kissow H, et al. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 2000;141:4013-20.
23. Dube PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology 2006;131:589-605.
24. Orskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 2005;124:105-12.
25. Miettinen PJ, Berger JE, Meneses J, et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995;376:337-41.
26. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50.
27. Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 1997;272:E1050-8.
28. Cheeseman CI, Tsang R. The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport. Am J Physiol 1996;271:G477-82.
29. Cheeseman CI. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am J Physiol 1997;273:R1965-71.
30. Cheeseman CI, O'Neill D. Basolateral D-glucose transport activity along the crypt-villus axis in rat jejunum and upregulation induced by gastric inhibitory peptide and glucagon-like peptide-2. Exp Physiol 1998;83:605-16.
31. Kato Y, Yu D, Schwartz MZ. Growth factor enhancement of intestinal function: dramatic response but lack of synergism. J Pediatr Surg 1997;32:1598-600.
32. Kato Y, Hamada Y, Ito S, Okumura T, Hioki K. Epidermal growth factor stimulates the recovery of glucose absorption after small bowel transplantation. J Surg Res 1998;80:315-9.
33. Kato Y, Yu D, Schwartz MZ. Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. J Pediatr Surg 1999;34:18-20.
34. Kitchen PA, Fitzgerald AJ, Goodlad RA, et al. Glucagon-like peptide-2 increases sucrase-isomaltase but not caudal-related homeobox protein-2 gene expression. Am J Physiol Gastrointest Liver Physiol 2000;278:G425-8.
35. Schwartz MZ, Storozuk RB. Influence of epidermal growth factor on intestinal function in the rat: comparison of systemic infusion versus luminal perfusion. Am J Surg 1988;155:18-22.
36. Schwartz MZ, Kato Y, Yu D, Lukish JR. Growth-factor enhancement of compromised gut function following massive small-bowel resection. Pediatr Surg Int 2000;16:174-5.
37. Lemoine NR, Leung HY, Gullick WJ. Growth factors in the gastrointestinal tract. Gut 1992;33:1297-300.
38. Playford RJ. Peptides and gastrointestinal mucosal integrity. Gut 1995;37:595-7.
39. Playford RJ, Hanby AM, Gschmeissner S, Peiffer LP, Wright NA, McGarrity T. The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract. Gut 1996;39:262-6.
40. Playford RJ, Wright NA. Why is epidermal growth factor present in the gut lumen? Gut 1996;38:303-5.
41. Troyer KL, Luetteke NC, Saxon ML, Qiu TH, Xian CJ, Lee DC. Growth retardation, duodenal lesions, and aberrant ileum architecture in triple null mice lacking EGF, amphiregulin, and TGF-α. Gastroenterology 2001;121:68-78.
42. Ritland SR, Gendler SJ, Burgart LJ, et al. Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in ApcMin mice but induces duodenal injury. Cancer Res 2000;60:4678-81.
43. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001;120:806-15.
44. Read NW, McFarlane A, Kinsman RI, et al. Effect of infusion of nutrient solutions into the ileum on gastrointestinal transit and plasma levels of neurotensin and enteroglucagon. Gastroenterology 1984;86:274-80.
45. Wojdemann M, Wettergren A, Hartmann B, Hilsted L, Holst JJ. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999;84:2513-7.
46. Wojdemann M, Wettergren A, Hartmann B, Holst JJ. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998;33:828-32.
47. Thulesen J, Hartmann B, Hare KJ, et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 2004;53:1145-50.